Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	OF CHANGES IN	N BENEFICIAL	OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     McKune John					2. Issuer Name <b>and</b> Ticker or Trading Symbol Carbylan Therapeutics, Inc. [ CBYL ]					(Ch	Relationship of eck all applications  Officer	able)	g Pers	on(s) to Issu 10% Ow Other (s)	ner	
	`	HERAPEUTIC	(Middle) S, INC.		3. Date of Earliest Transaction (Month/Day/Year) 11/02/2015							X Officer (give title below)  See Remarks				
(Street)	LTO C	A	94304	4.	If Ame	ndment, I	Date (	of Original File	ed (Month/Da	ay/Year)	Line	X Form f	led by One	Repo	(Check App rting Person One Report	
(City)	(S:	•	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			Beneficia	es Form ally (D) o Following (I) (Ir		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			1130.4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ersion ercise (Month/Day/Year) of ative	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$4.01	11/02/2015		A		50,000		(1)	11/02/2025	Common Stock	50,000	\$0.00	50,000		D	

## **Explanation of Responses:**

1. The option shall vest with respect to one-quarter of the underlying shares upon the first anniversary of the vesting commencement date of August 5, 2015, and then with respect to the remaining shares monthly thereafter over the next three years.

## Remarks:

Corporate Controller & Principal Accounting Officer

By: /s/ David J. Saul, Attorney-11/04/2015

in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.